Login / Signup

Decoding the specificity of m 6 A RNA methylation and its implication in cancer therapy.

Yixian CunWenbing GuoBiao MaYasushi OkunoJinkai Wang
Published in: Molecular therapy : the journal of the American Society of Gene Therapy (2024)
N6-methyladenosine (m 6 A) is the most abundant endogenous modification in eukaryotic RNAs. It plays important roles in various biological processes and diseases, including cancers. More and more studies have revealed that the deposition of m 6 A is specifically regulated in a context-dependent manner. Here, we review the diverse mechanisms that determine the topology of m 6 A along RNAs and the cell-type-specific m 6 A methylomes. The exon junction complex (EJC) as well as histone modifications play important roles in determining the topological distribution of m 6 A along nascent RNAs, while the transcription factors and RNA-binding proteins, which usually bind specific DNAs and RNAs in a cell-type-specific manner, largely account for the cell-type-specific m 6 A methylomes. Due to the lack of specificity of m 6 A writers and readers, there are still challenges to target the core m 6 A machinery for cancer therapies. Therefore, understanding the mechanisms underlying the specificity of m 6 A modifications in cancers would be important for future cancer therapies through m 6 A intervention.
Keyphrases
  • transcription factor
  • cancer therapy
  • papillary thyroid
  • randomized controlled trial
  • dna methylation
  • childhood cancer
  • gene expression
  • single cell
  • young adults
  • structural basis